Hispanics in Treatment: The Loxapine Experience
Since 1975 the authors have been using Loxapine Succinate/ Hydrochloride [Loxitane (R)] in a variety of psychotic disorders such as Acute and Paranoid Schizophrenia, Bipolar Disorder, specifically the Manic Phase, in conjunction with Lithium Carbonate, Acute and Chronic Brain disorder and/or any psychotic disorder where loss of contact with reality (delusions and hallucinations) and agitation are cardinal symptoms.
KeywordsTardive Dyskinesia Psychotic Disorder Ergot Alkaloid Chronic Schizophrenia Hispanic Patient
Unable to display preview. Download preview PDF.
- 3.Gomez, E., “Comparison of Loxapine, Chlorpromazine and Placebo,” Grand Rounds, George London Mem. Hosp. Chicago, IL, June 1976,Google Scholar
- 4.Gomez, E., “Loxapine vs. Haloperidol, Clinical Observations in Acute Schizophrenia,” paper read at Clinical Conference, George London Memorial Hospital, Chicago, IL, November 1976.Google Scholar
- 5.Arce, A., Torres-Matrullo, C, “Acculturation: Its Impact on Treatment Strategies,” paper read “The Hispanic American Symposium,” A.P.A. Annual Meeting, Atlanta, GA, May 1978.Google Scholar
- 6.Gomez, E., “Clinical Observations In The Treatment of Tardive Dyskinesia with Dihydrogenated Ergot Alkaloids (Hydergine), Preliminary Findings,” Psych. J. Univ. Ottawa, Vol. II, No. 2, July 1977.Google Scholar
- 7.Gomez, E., “The Chronic Patient, Patterns of Rehabilitation,” paper read to the Faculty Ottawa University — School of Medicine, Dept. of Psychiatry, Ottawa, Canada, March 1982.Google Scholar
- 11.Weidley EF, Setler PE, Rush JA:Google Scholar
- 13.Gomez, M., Gomez, E., “Hispanics in Treatment: The Amoxapine Experience,” paper read at the Symposium “The Treatment of Hispanic Patients in the U.S.A.” at the VII World Congress of Psychiatry, Vienna, Austria, July 198.Google Scholar